Hexa Health Care Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Hexa Health Care Private Limited Pharmaceutical Export Portfolio Dataset — 7 Products, $1.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hexa Health Care Private Limited — Pharmaceutical Exporter Profile (2026) | 7 Products, $1.0M Trade | TransData Nexus

Hexa Health Care Private Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $1.0M Total Trade · DGFT Verified

Hexa Health Care Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.0M across 7 products in 5 therapeutic categories. Based on 349 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Empagliflozin ($675.4K), Ivermectin ($201.5K), Tiotropium ($76.4K).

Hexa Health Care Private Limited — Export Portfolio & Destination Treemap

Hexa Health Care Private Limited pharmaceutical export portfolio — 7 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Hexa Health Care Private Limited? — Company Overview & Market Position

Hexa Health Care Private Limited, established on May 24, 2005, is a private limited company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2005PTC153478. Its authorized capital is ₹5.00 million, with a paid-up capital of ₹3.20 million. The registered office is located at Bhiwandiwala Building, 194 Dattaram Lad Marg, Kalachowki, Mumbai, Maharashtra, 400033.

Hexa Health Care Private Limited operates in the pharmaceutical sector, focusing on the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is unlisted and has been active in the industry for over two decades. As of November 3, 2025, the company is led by two directors: Niren Mansukhlal Shah and Piyush Bharat Shah.

What Does Hexa Health Care Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Empagliflozin$675.4K 2Ivermectin

Product Portfolio — Top 7 by Export Value

Hexa Health Care Private Limited exports 7 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Empagliflozin	Diabetes & Endocrine	$675.4K	113	10.1%	3
2	Ivermectin	Antimalarial & Antiparasitic	$201.5K	28	2.3%	10
3	Tiotropium	Respiratory	$76.4K	79	0.1%	6
4	Semaglutide	Advanced Diabetes Medications	$42.2K	53	0.8%	15
5	Torsemide	Diuretics	$33.5K	60	0.2%	13
6	Saxagliptin	Advanced Diabetes Medications	$4.0K	9	0.1%	7
7	Canagliflozin	Advanced Diabetes Medications	$3.0K	7	0.3%	10

Hexa Health Care Private Limited exports 7 pharmaceutical products across 5 therapeutic categories with a total export value of $1.0M. The top category is Diabetes & Endocrine (65.2% of portfolio), followed by Antimalarial & Antiparasitic (19.4%), indicating a concentrated portfolio with the top 5 products accounting for 99.3% of total export value.

Hexa Health Care Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Hexa Health Care Private Limited's manufacturing facilities, including their locations, capacities, and specializations, are not publicly disclosed. The company is registered under the Corporate Identification Number (CIN) U24230MH2005PTC153478, indicating its involvement in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products.

3Key Leadership

The leadership team of Hexa Health Care Private Limited comprises:

Niren Mansukhlal Shah: Director since May 24, 2005.

Piyush Bharat Shah: Additional Director since November 26, 2024.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Hexa Health Care Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Hexa Health Care Private Limited's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not publicly documented. The company's export activities, as per TransData Nexus proprietary trade data, amount to $1.0 million USD across 349 shipments, with a portfolio concentration of 99.3% in its top five products. However, specific regulatory filings, approvals, and market access statuses in these regions are not available in the provided sources.

2Emerging Markets

The company's export data indicates a significant focus on the Diabetes & Endocrine therapeutic category, accounting for 65.2% of its exports. This suggests potential penetration into emerging markets where diabetes prevalence is rising. However, specific information regarding the company's presence in Africa, Latin America, or Southeast Asia, and whether it holds WHO prequalification for these regions, is not available in the provided sources.

3Geographic Strategy

Hexa Health Care Private Limited's export portfolio is highly concentrated, with its top five products comprising 99.3% of total exports. This indicates a focused geographic strategy, potentially targeting markets with high demand for these specific products. However, the lack of detailed information on the company's geographic diversification and strategic direction limits a comprehensive assessment of its concentration risk and future outlook.

Hexa Health Care Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Hexa Health Care Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide insights into its regulatory standing with the U.S. Food and Drug Administration (FDA).

2WHO & EU GMP

Information regarding Hexa Health Care Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not available in the provided sources.

3CDSCO & Indian Regulatory

Specific details about Hexa Health Care Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly disclosed. The company's registration under CIN U24230MH2005PTC153478 indicates its compliance with Indian regulatory requirements for pharmaceutical manufacturing.

Hexa Health Care Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Hexa Health Care Private Limited operates in the pharmaceutical sector, competing with various domestic and international companies. However, specific information regarding its top competitors in overlapping categories, market share comparisons, and head-to-head analyses is not available in the provided sources.

2Key Differentiators

Hexa Health Care Private Limited's key differentiators include its focused product portfolio, with a significant emphasis on the Diabetes & Endocrine therapeutic category, and its extensive experience in the pharmaceutical manufacturing sector. However, detailed insights into its unique strengths, competitive advantages, and product portfolio distinctions are limited due to the lack of comprehensive public information.

3Strategic Position

The company's strategic direction appears to be focused on the manufacturing and export of finished pharmaceutical formulations, particularly in the Diabetes & Endocrine therapeutic category. However, without detailed information on its product development pipeline, market expansion plans, or future outlook, a comprehensive assessment of its current strategic position and future direction is not feasible.

Buyer Due Diligence Brief — Evaluating Hexa Health Care Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Hexa Health Care Private Limited's export data indicates a consistent volume of shipments, with a total of 349 shipments valued at $1.0 million USD. The portfolio concentration of 99.3% in its top five products suggests a focused approach to its export activities. However, without detailed information on the company's supply chain practices, quality control measures, and reliability indicators, a thorough assessment of its overall track record and consistency as a supplier cannot be conducted.

2Certifications to Verify

Importers considering Hexa Health Care Private Limited as a supplier should verify the following certifications:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulatory standards.

WHO-GMP Certification: Verify the company's compliance with World Health Organization Good Manufacturing Practice standards to ensure product quality and safety.

Frequently Asked Questions — Hexa Health Care Private Limited

How many pharmaceutical products does Hexa Health Care Private Limited export from India?

Hexa Health Care Private Limited exports 7 pharmaceutical products across 5 therapeutic categories. The top exports are Empagliflozin ($675.4K), Ivermectin ($201.5K), Tiotropium ($76.4K), Semaglutide ($42.2K), Torsemide ($33.5K). Total export value is $1.0M.

What is Hexa Health Care Private Limited's total pharmaceutical export value?

Hexa Health Care Private Limited's total pharmaceutical export value is $1.0M, based on 349 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Hexa Health Care Private Limited cover?

Hexa Health Care Private Limited exports across 5 therapeutic categories. The largest are Diabetes & Endocrine (65.2%, 1 products), Antimalarial & Antiparasitic (19.4%, 1 products), Respiratory (7.4%, 1 products).

Get Full Hexa Health Care Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.